308080 바이젠셀
기본 정보
- 섹터: KOSDAQ:일반서비스
- 시가총액: 1,281억원 (2026-06-30 기준)
- 첫 등장: — (마커 미등장)
- 태그: 매크로/바이오헬스 · 세포치료제 · 면역치료 · 항암 · T세포
- 네이버 금융: 🔗
기업개요
- 동사는 2013년 설립된 바이오 벤처로 신규 의약품 연구개발 및 면역세포치료제 개발·제조를 함.
- 2021년 기술성장기업으로 코스닥에 상장하였고, 가톨릭대 의과대학과의 협력 모델을 통해 세포치료제 전문기업으로 성장하고 있음.
- NK/T세포 림프종 대상 VT-EBV-N이 임상 2상을 완료해 조건부 품목허가를 준비 중이며, 교모세포종 VC-302와 간세포암 VC-420은 전임상 단계 iPSC 유래 NK세포 기반 치료제로 개발하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | 5,350 | 5,400 | 🔴 +0.93% | — | ×0.5 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | -0.0 |
| 2026-08-06 | 5,330 | 5,350 | 🔴 +0.38% | — | ×0.8 | 🔻 개인 | -0.4억 | -0.4 | +0.0 | +0.0 | +0.0 | +0.4 | +0.0 |
| 2026-08-05 | 5,140 | 5,330 | 🔴 +3.70% | — | ×0.7 | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.0 | +0.3 | +0.0 |
| 2026-08-04 | 4,855 | 5,140 | 🔴 +5.87% | — | ×0.8 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-08-03 | 4,770 | 4,855 | 🔴 +1.78% | — | ×0.5 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.2 | +0.0 |
| 2026-07-31 | 4,430 | 4,770 | 🔴 +7.67% | — | ×0.6 | 🟢 외인 | +1.7억 | +1.7 | +0.0 | +0.0 | +0.0 | -1.7 | +0.0 |
| 2026-07-30 | 4,555 | 4,430 | 🔵 -2.74% | — | ×0.5 | 🟢 외인 | +1.0억 | +1.0 | +0.0 | +0.0 | +0.0 | -1.0 | -0.0 |
| 2026-07-29 | 4,815 | 4,555 | 🔵 -5.40% | — | ×1.2 | 🟢 외인 | +2.0억 | +2.0 | +0.0 | -0.0 | +0.0 | -1.9 | -0.2 |
| 2026-07-28 | 5,190 | 4,815 | 🔵 -7.23% | — | ×0.7 | 🔻 개인 | -0.7억 | -0.7 | +0.0 | +0.0 | +0.0 | +0.6 | +0.1 |
| 2026-07-27 | 5,210 | 5,190 | 🔵 -0.38% | — | ×0.3 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | -0.0 |
| 2026-07-24 | 5,400 | 5,210 | 🔵 -3.52% | — | ×0.5 | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.0 | +0.3 | +0.0 |
| 2026-07-23 | 5,090 | 5,400 | 🔴 +6.09% | — | ×0.5 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | -0.0 | +0.0 | -1.2 | +0.0 |
| 2026-07-22 | 5,070 | 5,090 | 🔴 +0.39% | — | ×0.5 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | -0.0 | +0.0 | -1.2 | +0.0 |
| 2026-07-21 | 5,150 | 5,070 | 🔵 -1.55% | — | ×0.5 | ⚫ 그외 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-20 | 5,510 | 5,150 | 🔵 -6.53% | — | ×0.5 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | -0.0 | +0.0 | +0.2 | +0.0 |
| 2026-07-16 | 5,880 | 5,510 | 🔵 -6.29% | — | ×0.6 | 🔻 개인 | -0.6억 | -0.6 | +0.0 | +0.0 | +0.0 | +0.6 | +0.0 |
| 2026-07-15 | 5,190 | 5,880 | 🔴 +13.29% | — | ×0.9 | 🟢 외인 | +1.4억 | +1.4 | +0.0 | -0.0 | +0.0 | -1.2 | -0.1 |
| 2026-07-14 | 5,390 | 5,190 | 🔵 -3.71% | — | ×0.9 | ⚫ 그외 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.1 |
| 2026-07-13 | 5,520 | 5,390 | 🔵 -2.36% | — | ×1.9 | 🔻 개인 | -3.1억 | -3.1 | +0.0 | -0.0 | +0.0 | +3.1 | +0.0 |
| 2026-07-10 | 5,540 | 5,520 | 🔵 -0.36% | — | ×0.5 | 🟢 외인 | +0.5억 | +0.5 | +0.0 | +0.0 | +0.0 | -0.6 | +0.0 |
| 2026-07-09 | 5,840 | 5,540 | 🔵 -5.14% | — | ×1.3 | 🟢 외인 | +1.0억 | +1.0 | +0.0 | +0.0 | +0.0 | -1.0 | -0.0 |
| 2026-07-08 | 5,510 | 5,840 | 🔴 +5.99% | — | ×1.9 | 🔻 개인 | -8.0억 | -8.0 | +0.0 | -0.1 | +0.0 | +8.2 | -0.1 |
| 2026-07-07 | 5,550 | 5,510 | 🔵 -0.72% | — | ×0.7 | 🟢 외인 | +1.1억 | +1.1 | +0.0 | +0.1 | +0.0 | -1.2 | +0.0 |
| 2026-07-06 | 5,680 | 5,550 | 🔵 -2.29% | — | ×0.7 | 🟢 외인 | +0.4억 | +0.4 | +0.0 | +0.0 | +0.0 | -0.4 | +0.0 |
| 2026-07-03 | 5,740 | 5,680 | 🔵 -1.05% | — | ×0.8 | 🟢 외인 | +1.5억 | +1.5 | +0.0 | -0.1 | +0.0 | -1.2 | -0.2 |
| 2026-07-02 | 6,140 | 5,740 | 🔵 -6.51% | — | ×0.8 | 🔻 개인 | -1.1억 | -1.1 | +0.0 | -0.1 | +0.0 | +1.2 | +0.0 |
| 2026-07-01 | 6,250 | 6,140 | 🔵 -1.76% | — | ×0.8 | 🟢 외인 | +2.5억 | +2.4 | +0.0 | +0.2 | +0.0 | -2.6 | -0.0 |
| 2026-06-30 | 6,420 | 6,250 | 🔵 -2.65% | — | ×0.7 | 🔻 개인 | -2.9억 | -2.9 | +0.0 | +0.0 | +0.0 | +2.8 | +0.0 |
| 2026-06-29 | 6,030 | 6,420 | 🔴 +6.47% | — | ×0.6 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | +0.0 | +0.0 | -1.4 | +0.1 |
| 2026-06-26 | 6,370 | 6,030 | 🔵 -5.34% | — | ×0.9 | 🟢 외인 | +5.1억 | +5.1 | +0.0 | +0.0 | +0.0 | -5.1 | +0.0 |
| 2026-06-25 | 6,610 | 6,370 | 🔵 -3.63% | — | ×0.7 | 🟢 외인 | +1.4억 | +1.4 | +0.0 | +0.0 | +0.0 | -1.2 | -0.2 |
| 2026-06-17 | 7,590 | 7,630 | 🔴 +0.53% | — | ×0.7 | 🟢 외인 | +0.8억 | +0.8 | +0.0 | +0.1 | -0.8 | -0.1 | |
| 2026-06-16 | 7,880 | 7,590 | 🔵 -3.68% | — | ×0.8 | 🟢 외인 | +8.1억 | +8.1 | +0.0 | -0.0 | -8.0 | -0.0 | |
| 2026-06-15 | 7,980 | 7,880 | 🔵 -1.25% | — | ×0.5 | 🟢 외인 | +4.8억 | +4.8 | +0.0 | +0.0 | -4.9 | +0.1 | |
| 2026-06-12 | 9,270 | 7,980 | 🔵 -13.92% | — | ×0.9 | 🔻 개인 | -26.1억 | -26.1 | +0.0 | +0.0 | +25.1 | +0.9 | |
| 2026-06-11 | 9,310 | 9,270 | 🔵 -0.43% | — | ×0.2 | 🟢 외인 | +0.8억 | +0.8 | +0.0 | +0.0 | -0.9 | +0.1 | |
| 2026-06-10 | 9,830 | 9,310 | 🔵 -5.29% | — | ×0.2 | 🔻 개인 | -0.5억 | -0.5 | +0.0 | -0.0 | +0.4 | +0.2 | |
| 2026-06-09 | 10,000 | 9,830 | 🔵 -1.70% | — | ×0.2 | 🟢 외인 | +0.6억 | +0.6 | +0.0 | +0.0 | -0.5 | -0.1 | |
| 2026-06-08 | 9,500 | 10,000 | 🔴 +5.26% | — | ×0.5 | 🔻 개인 | -1.6억 | -1.6 | +0.0 | +0.0 | +1.3 | +0.3 | |
| 2026-06-05 | 9,780 | 9,500 | 🔵 -2.86% | — | ×0.2 | 🔻 개인 | -1.9억 | -1.9 | +0.0 | +0.0 | +1.9 | +0.0 | |
| 2026-06-04 | 10,000 | 9,780 | 🔵 -2.20% | — | ×0.3 | 🔻 개인 | -1.0억 | -1.0 | +0.0 | +0.0 | +0.9 | +0.1 | |
| 2026-06-02 | 12,080 | 10,000 | 🔵 -17.22% | — | ×0.5 | 🔻 개인 | -1.4억 | -1.4 | +0.0 | +0.0 | +1.4 | -0.0 | |
| 2026-06-01 | 13,590 | 12,080 | 🔵 -11.11% | — | ×0.6 | 🔻 개인 | -4.8억 | -4.8 | +0.0 | +0.0 | +5.0 | -0.2 | |
| 2026-05-29 | 13,180 | 13,590 | 🔴 +3.11% | — | ×0.8 | 🔻 개인 | +1.2억 | +1.2 | +0.0 | +0.0 | +1.8 | -3.1 |
일자별 사유 (최신 위)
2026-07-15
- 사유: —
- 섹터 컨텍스트: KOSDAQ:일반서비스 (smart +166억)
- 매크로 원인: HLB 리보세라닙 FDA 제조 리스크 해소 기대에 그룹주 무더기 상한가, 미프진 허가 검토·항암신약 모멘텀 가세 (보통)